The bacillus Calmette–Guerin (BCG) vaccine for tuberculosis (TB) has been shown to be effective in the treatment of bladder cancer by macropinocytic delivery, which is dependent on RAC1, CDC42, and its effector PAK1 [112]. Here, RAC1 is linked to tuberculosis.